早发性卵巢功能不全的临床诊治进展

doi:10.6040/j.issn.1671-7554.0.2017.1293

摘要/Abstract

摘要： 早发性卵巢功能不全(POI)是指在妇女40岁之前卵巢功能明显衰退或丧失的临床综合征,严重影响女性生育健康及身心健康。POI病因包括遗传性因素、免疫性因素、医源性因素等,但大多数患者病因仍不明确,其具体发病机制仍有待进一步研究。POI患者的生育能力明显下降,但目前尚无改善POI生育力的有效方法,激素补充治疗(HRT)是预防和治疗继发于POI的各系统并发症的有效手段。近年来,国内外研究提供许多新的依据,但是尚存许多未解之谜,本文将主要对POI的临床进展进行综述。

关键词: 早发性卵巢功能不全, 体外受精-胚胎移植, 激素替代治疗, 生育力保存

Abstract: Premature ovarian insufficiency(POI)is a clinical syndrome manifested with significant decline or loss of ovarian activity before the age of 40 years, which has serious effects on the reproductive, physical and mental health of women. The causes of POI are involved with genetic factors, immunological factors and iatrogenic factors, and the etiology of most patients remains unclear. The fertility of POI patients dramatically decreases, but there is no satisfactory treatment so far. Hormone replacement therapy(HRT)is considered an effectively preventative and therapeutic option to manage complications related to POI. Although many researchers have focused on the mechanism, diagnosis and treatment of POI in recent years, much remains to be explored. This article will review the clinical research advances on POI.

Key words: Premature ovarian insufficiency, In vitro fertilization-embryo transfer, Hormone replacement therapy, Fertility preservation

中图分类号:

R711.75

陈士岭,周星宇. 早发性卵巢功能不全的临床诊治进展[J]. 山东大学学报 (医学版), 2018, 56(4): 1-7.

CHEN Shiling, ZHOU Xingyu. Clinical research advances on premature ovarian insufficiency[J]. Journal of Shandong University (Health Sciences), 2018, 56(4): 1-7.

参考文献

[1] Committee on Gynecologic Practice. Committee opinion No. 698: hormone therapy in primary ovarian insufficiency[J]. Obstet Gynecol, 2017, 129(5): e134-e141.
[2] Committee opinion No. 605: primary ovarian insufficiency in adolescents and young women[J]. Obstet Gynecol, 2014, 124(1): 193-197.
[3] The ESHRE Guideline Group on POI, Webber L, Davies M, et al. ESHRE Guideline: management of women with premature ovarian insufficiency[J]. Hum Reprod, 2016, 31(5): 926-937.
[4] 陈子江, 田秦杰, 乔杰, 等. 早发性卵巢功能不全的临床诊疗中国专家共识[J]. 中华妇产科杂志, 2017, 52(9): 577-581.
[5] Tal R, Seifer DB. Ovarian reserve testing: a users guide[J]. Am J Obstet Gynecol, 2017, 217(2): 129-140.
[6] Visser JA, Schipper I, Laven JS, et al. Anti-mullerian hormone: an ovarian reserve marker in primary ovarian insufficiency[J]. Nat Rev Endocrinol, 2012, 8(6): 331-341.
[7] Knauff EAH, Eijkemans MJC, Lambalk CB, et al. Anti-müllerian hormone, inhibin B, and antral follicle count in young women with ovarian failure[J]. J Clin Endocrinol Metab, 2009, 94(3): 786-792.
[8] Kallio S, Aittomaki K, Piltonen T, et al. Anti-mullerian hormone as a predictor of follicular reserve in ovarian insufficiency: special emphasis on FSH-resistant ovaries[J]. Hum Reprod, 2012, 27(3): 854-860.
[9] Jiao X, Zhang H, Ke H, et al. Premature ovarian insufficiency: phenotypic characterization within different etiologies[J]. J Clin Endocrinol Metab, 2017, 102(7): 2281-2290.
[10] Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure[J]. Clin Endocrinol, 2008, 68(4): 499-509.
[11] Shestakova IG, Radzinsky VE, Khamoshina MB. Occult form of premature ovarian insufficiency[J]. Gynecol Endocrinol, 2016, 32(sup2): 30-32.
[12] Streuli I, Fraisse T, Ibecheole V, et al. Intermediate and premutation FMR1 alleles in women with occult primary ovarian insufficiency[J]. Fertil Steril, 2009, 92(2): 464-470.
[13] Kushnir VA, Safdie M1, Darmon SK, et al. Age-specific IVF outcomes in infertile women with baseline FSH levels ≥20 mIU/mL[J]. Reprod Sci, 2017: 1933719117697130. doi:10.1177/1933719117697130.
[14] Tucker EJ, Grover SR, Bachelot A, et al. Premature ovarian insufficiency: new perspectives on genetic cause and phenotypic spectrum[J]. Endocr Rev, 2016, 37(6): 609-635.
[15] Lakhal B, Braham R, Berguigua R, et al. Cytogenetic analyses of premature ovarian failure using karyotyping and interphase fluorescence in situ hybridization(FISH)in a group of 1000 patients[J]. Clin Genet, 2010, 78(2): 181-185.
[16] Baronchelli S, Conconi D, Panzeri E, et al. Cytogenetics of premature ovarian failure: an investigation on 269 affected women[J]. J Biomed Biotechnol, 2011, 2011: 370195. doi:10.1155/2011/370195.
[17] Jiao X, Qin C, Li J, et al. Cytogenetic analysis of 531 Chinese women with premature ovarian failure[J]. Hum Reprod, 2012, 27(7): 2201-2207.
[18] Kalantari H, Madani T, Zari MS, et al. Cytogenetic analysis of 179 Iranian women with premature ovarian failure[J]. Gynecol Endocrinol, 2013, 29(6): 588-591.
[19] Rossetti R, Ferrari I, Bonomi M, et al. Genetics of primary ovarian insufficiency[J]. Clin Genet, 2017, 91(2): 183-198.
[20] Guo T, Qin Y, Jiao X, et al. FMR1 Premutation is an uncommon explanation for premature ovarian failure in han Chinese[J]. PLoS One, 2014, 9(7): e103316. doi:10.1371/journal.pone.0103316.
[21] Qin Y, Jiao X, Simpson JL, et al. Genetics of primary ovarian insufficiency: new developments and opportunities[J]. Hum Reprod Update, 2015, 21(6): 787-808.
[22] Tšuiko O, Nõukas M, Žilina O, et al. Copy number variation analysis detectsnovel candidate genes involved infollicular growth and oocyte maturationin a cohort of premature ovarian failure cases[J]. Hum Reprod, 2016, 31(8): 1913-1925.
[23] Komorowska B. Autoimmune premature ovarian failure[J]. Prz Menopauzalny, 2016, 15(4): 210-214.
[24] Gao J, Jiao X, Dang Y, et al. Identification of patients with primary ovarian insufficiency caused by autoimmunity[J]. Reprod Biomed Online, 2017, 35(4): 475-479.
[25] Forges T, Monnier-Barbarino P, Faure GC, et al. Autoimmunity and antigenic targets in ovarian pathology[J]. Hum Reprod Update, 2004, 10(2): 163-175.
[26] Dragojevic-Dikic S, Marisavljevic D, Mitrovic A, et al. An immunological insight into premature ovarian failure(POF)[J]. Autoimmun Rev, 2010, 9(11): 771-774.
[27] Silva CA, Yamakami LYS, Aikawa NE, et al. Autoimmune primary ovarian insufficiency[J]. Autoimmun Rev, 2014, 13(4-5): 427-430.
[28] Mohamed AA, Al-Hussaini TK, Fathalla MM, et al. The impact of excision of benign nonendometriotic ovarian cysts on ovarian reserve: a systematic review[J]. Am J Obstet Gynecol, 2016, 215(2): 169-176.
[29] Ye X, Yang Y, Sun X. A retrospective analysis of the effect of salpingectomyon serum anti-Müllerian hormonelevel and ovarian reserve[J]. Am J Obstet Gynecol, 2015, 212(1): 51-53.
[30] Irtan S, Orbach D, Helfre S, et al. Ovarian transposition in prepubescent and adolescent girls with cancer[J]. Lancet Oncol, 2013, 14(13): e601-e608.
[31] Overbeek A, van den Berg MH, van Leeuwen FE, et al. Chemotherapy-related late adverse effects on ovarian function in female survivors of childhood and young adult cancer: A systematic review[J]. Cancer Treat Rev, 2017, 53: 10-24.
[32] Keilholz U, Korbling M, Fehrentz D, et al. Long-term endocrine toxicity of myeloablative treatment followed by autologous bone marrow/blood derived stem cell transplantation in patients with malignant lymphohematopoietic disorders[J]. Cancer, 1989, 64(3): 641-645.
[33] Whitehead E, Shalet SM, Blackledge G, et al. The effect of combination chemotherapy on ovarian function in women treated for Hodgkin's disease[J]. Cancer, 1983, 52(6): 988-993.
[34] 俞健梅, 马艳萍, 李永刚, 等. 环境内分泌干扰物对生殖健康影响的研究进展[J]. 现代生物医学进展, 2014, 14(31): 6197-6200. YU Jianmei, MA Yanping, LI Yonggang, et al. The research progress on the effect of the reproductive health by the environmental endocrine disruptors[J]. Progress in Modern Biomedicine, 2014, 14(31): 6197-6200.
[35] Vabre P, Gatimel N, Moreau J, et al. Environmental pollutants, a possible etiology for premature ovarian insufficiency: a narrative review of animal and human data[J]. Environ Health, 2017, 16(1): 37. doi:10.1186/s12940-017-0242-4.
[36] Nelson LM. Primary ovarian insufficiency[J]. N Engl J Med, 2009, 360(6): 606-614.
[37] Bachelot A, Nicolas C, Bidet M, et al. Long-term outcome of ovarian function in women with intermittent premature ovarian insufficiency[J]. Clin Endocrinol, 2017, 86(2): 223-228.
[38] Chen X, Chen SL, Ye DS, et al. Retrospective analysis of reproductive outcomes in women with primary ovarian insufficiency showing intermittent follicular development[J]. Reprod Biomed Online, 2016, 32(4): 427-433.
[39] 马伟旭, 陈薪, 周星宇, 等. 早发性卵巢功能不全患者应用卵胞浆内单精子显微注射-胚胎移植获妊娠分娩1例及文献复习[J]. 南方医科大学学报, 2017, 37(10): 1418-1422. MA Weixu, CHEN Xin, ZHOU Xingyu, et al. Successful pregnancy following intracytoplasmic sperm injection-embryo transfer in a patient with premature ovarian insufficiency: a case report[J]. J South Med Univ, 2017, 37(10): 1418-1422.
[40] Ben-Nagi J, Panay N. Premature ovarian insufficiency: how to improve reproductive outcome?[J]. Climacteric, 2014, 17(3): 242-246.
[41] Kawamura K, Yuan C, Suzuki N, et al. Hippo signaling disruption and Akt stimulation of ovarian follicles for infertility treatment[J]. Proc Natl Acad Sci USA, 2013, 110(43): 17474-17479.
[42] Oyesanya OA, Olufowobi O, Ross W, et al. Prognosis of oocyte donation cycles: a prospective comparison of the in vitro fertilization-embryo transfer cycles of recipients who used shared oocytes versus those who used altruistic donors[J]. Fertil Steril, 2009, 92(3): 930-936.
[43] Podfigurna-Stopa A, Czyzyk A, Grymowicz M, et al. Premature ovarian insufficiency: the context of long-term effects[J]. J Endocrinol Invest, 2016, 39(9): 983-990.
[44] 廖彩韵, 梁晓燕. 女性生育力保存研究进展[J]. 实用妇产科杂志, 2013, 29(5): 339-342.
[45] Lara LA, Useche B, Ferriani RA, et al. The effects of hypoestrogenism on the vaginal wall: interference with the normal sexual response[J]. J Sex Med, 2009, 6(1): 30-39.
[46] Benetti-Pinto CL, Giraldo PC, Pacello PCC, et al. Vaginal epithelium and microflora characteristics in women with premature ovarian failure under hormone therapy compared to healthy women[J]. Arch Gynecol Obstet, 2015, 292(1): 159-164.
[47] Daan N, Muka T, Koster M, et al. Cardiovascular risk in women with premature ovarian insufficiency compared to premenopausal women at middle age[J]. J Clin Endocrinol Metab, 2016, 101(9): 3306-3315.
[48] Muka T, Oliver-Williams C, Kunutsor S, et al. Association of age at onset of menopause and time since onset of menopause with cardiovascular outcomes, intermediate vascular traits, and all-cause mortality: a systematic review and meta-analysis[J]. JAMA Cardiol, 2016, 1(7): 767-776.
[49] Sullivan SD, Sarrel PM, Nelson LM. Hormone replacement therapy in young women with primary ovarian insufficiency and early menopause[J]. Fertil Steril, 2016, 106(7): 1588-1599.
[50] Wu X, Cai H, Kallianpur A, et al. Impact of premature ovarian failure on mortality and morbidity among Chinese women[J]. PLoS One, 2014, 9(3): e89597. doi:10.1371/journal.pone.0089597.
[51] Asli IN, Fallahian M, Seddigh HR, et al. Evaluation of bone mineral density in premature ovarian failure[J]. Hell J Nucl Med, 2010, 13(3): 261-263.
[52] Popat VB, Calis KA, Vanderhoof VH, et al. Bone mineral density in estrogen-deficient young women[J]. J Clin Endocrinol Metab, 2009, 94(7): 2277-2283.
[53] Popat VB, Calis KA, Kalantaridou SN, et al. Bone mineral density in young women with primary ovarian insufficiency: results of a three-year randomized controlled trial of physiological transdermal estradiol and testosterone replacement[J]. J Clin Endocrinol Metab, 2014, 99(9): 3418-3426.
[54] Schmidt PJ, Cardoso GM, Ross JL, et al. Shyness, social anxiety, and impaired self-esteem in Turner syndrome and premature ovarian failure[J]. JAMA, 2006, 295(12): 1374-1376.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed